Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 871  

 
   Table of Contents      
LETTER TO EDITOR
Year : 2015  |  Volume : 14  |  Issue : 1  |  Page : 71

Accuracy of Positron Emission Tomography-Computed Tomography in Bone Marrow Involvement Lymphoma


1 Department of Hematology, Kocaeli Acibadem Hospital, Kocaeli, Turkey
2 Department of Internal Medicine, Bitlis Mutki State Hospital, Bitlis, Turkey
3 Department of Internal Medicine, Sakarya University Medical Faculty, Sakarya, Turkey

Date of Web Publication2-Feb-2015

Correspondence Address:
Serdar Olt
Department of Internal Medicine, Bitlis Mutki State Hospital, Bitlis
Turkey
Login to access the Email id


DOI: 10.4103/1450-1147.150564

PMID: 25709554

Rights and Permissions

How to cite this article:
Cekdemir D, Olt S, Ergenc H, Tamer A. Accuracy of Positron Emission Tomography-Computed Tomography in Bone Marrow Involvement Lymphoma. World J Nucl Med 2015;14:71

How to cite this URL:
Cekdemir D, Olt S, Ergenc H, Tamer A. Accuracy of Positron Emission Tomography-Computed Tomography in Bone Marrow Involvement Lymphoma. World J Nucl Med [serial online] 2015 [cited 2019 Dec 6];14:71. Available from: http://www.wjnm.org/text.asp?2015/14/1/71/150564

Dear Editor,

Spread of lymphoma should be determined before treatment modality. Bone marrow involvement is an important part of staging of lymphoma. Recently the most commonly used imaging modality in lymphoma is positron emission tomography-computed tomography (PET-CT). Glucose metabolic activity is high in most lymphoma and we can evaluate spread of lymphoma with PET-CT because of its high uptake of fluorodeoxyglucose. [1] Nowadays bone marrow biopsy and PET-CT is used routinely in order to staging of lymphoma. [2]

We aimed to test PET-CT in bone marrow involvement lymphoma. We included 15 lymphoma patients in our study, and all patients underwent bone marrow biopsy. PET-CT was applied all patients. 10 out of 15 (66.6%) patients showed positive PET-CT results. Positive pathological biopsy material were found in eight out of 15 patients (53.3%). 40% of PET-CT findings proved true positive, 26.6% were found to be false positive. 20% proved true negative and 13.3% false negative. This results in a specificity of 42.8% and a sensitivity of 75%.



Here we wanted to emphasis our experience of PET-CT in lymphoma.

 
   References Top

1.
Chavdarova LI, Tzonevska AD, Piperkova EN. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI. Hell J Nucl Med 2013;16:223-9.  Back to cited text no. 1
    
2.
Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006;47:1326-34.  Back to cited text no. 2
    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed987    
    Printed26    
    Emailed0    
    PDF Downloaded128    
    Comments [Add]    

Recommend this journal